Guidance for liver transplant immunosuppression

American Journal of Transplantation

Volumn 11, Issue 5, 2011, Pages 886-887

  Knechtle, S J ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

CLINICAL PRACTICE; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; EDITORIAL; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; KIDNEY INJURY; LEUKOPENIA; LIVER GRAFT; LIVER GRAFT REJECTION; PRIORITY JOURNAL;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 79955548854     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03488.x     Document Type: Editorial

References (4)

1. Boudjema K, Camus C, Saliba F, et al,. Reduced-dose tacrolimus with mycophenolatemofetil vs. standard-dose tacrolimus in liver transplantation: A randomized study. Am J Transplant 2011; current issue.
2. Meier-Kriesche HU, Li S, Gruessner RWG, et al,. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
3. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR,. Mycophenolatemofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transplant 2005; 11: 750-759. (Pubitemid 40975576)
4. Klintmalm GB, Washburn WK, Rudich SM, et al,. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transplant 2007; 13: 1521-1531. (Pubitemid 350168192)